Log In
Print
BCIQ
Print
Print this Print this
 

Claudetect 18.2 assay

  Manage Alerts
Collapse Summary General Information
Company Ganymed Pharmaceuticals AG
DescriptionSemi-quantitative immunohistochemical assay for the expression levels of CLDN18.2
Molecular Target
Mechanism of ActionDiagnostic
Therapeutic ModalityDiagnostics
Latest Stage of DevelopmentApproved
Standard IndicationCancer, Diagnostic
Indication DetailsAssess expression nlevels of CLDN18.2 in solid tumors
Regulatory Designation

EU - Standard Review (Assess expression nlevels of CLDN18.2 in solid tumors)

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today